{"nctId":"NCT04244084","briefTitle":"Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection","startDateStruct":{"date":"2019-10-08","type":"ACTUAL"},"conditions":["Viral Respiratory Infection"],"count":240,"armGroups":[{"label":"MMH-407","type":"EXPERIMENTAL","interventionNames":["Drug: MMH-407"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MMH-407","otherNames":["Raphamin"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients of either gender aged 18-70 years.\n2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 38.0°C at examination + total general symptoms score ≥4, nasal/throat/chest symptoms score ≥2.\n3. The first 24 hours after ARVI onset.\n4. Patients giving their consent to use reliable contraception during the study.\n5. Signed patient information sheet (informed consent form).\n\nExclusion Criteria:\n\n1. Clinical symptoms of severe influenza/ARVI requiring hospitalization.\n2. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of illness.\n3. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and other pathology).\n4. Patients requiring antiviral medication prohibited within the study.\n5. Medical history of primary and secondary immunodeficiency.\n6. Medical history/suspicion of oncology of any localization (except for benign neoplasms).\n7. Aggravation or decompensation of chronic diseases affecting a patient's ability to participate in the clinical trial.\n8. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.\n9. Allergy/ hypersensitivity to any component of the study drug.\n10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial.\n11. Course administration of the drug products specified in the section \"Prohibited Concomitant Therapy\" within two weeks prior to inclusion in the study.\n12. Patients who will not fulfill the requirements during the study or follow the order of administration of the studied drug products, from the Investigator's point of view.\n13. Medical history of mental diseases, alcoholism or drug abuse that according to the investigator's opinion will compromise compliance with the study procedures.\n14. Participation in other clinical trials for 3 months prior to enrollment in this study.\n15. Patients who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).\n16. Patients who work for OOO \"NPF \"MATERIA MEDICA HOLDING\" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms","description":"Outcome Measure is evaluated on the basis of the \"ARVI severity scale\" to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR).\n\nARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from \"0\" to \"39\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.9"},{"groupId":"OG001","value":"5.0","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)","description":"Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was \"0\" and the maximum value was \"234\" units (day\\*score). Higher TSS and AUC scores meant worse results.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":"21.7"},{"groupId":"OG001","value":"52.6","spread":"24.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)","description":"ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from \"0\" to \"39\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)","description":"Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from \"0\" to \"39\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"2.2"},{"groupId":"OG001","value":"4.8","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)","description":"Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nAcute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from \"0\" to \"39\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Dosing Frequency of Antipyretics.","description":"Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.68"},{"groupId":"OG001","value":"0.38","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.48"},{"groupId":"OG001","value":"0.24","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.22"},{"groupId":"OG001","value":"0.04","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Reporting Worsening of Illness","description":"Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence and Characteristics of Adverse Events (AEs)","description":"Severity of AEs, its causal relationship to the study drug, and outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Blood Pressure.","description":"Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.0","spread":"10.0"},{"groupId":"OG001","value":"121.0","spread":"10.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.0","spread":"8.5"},{"groupId":"OG001","value":"120.0","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.0","spread":"8.2"},{"groupId":"OG001","value":"119.0","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":"7.5"},{"groupId":"OG001","value":"75.1","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":"6.3"},{"groupId":"OG001","value":"74.8","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":"6.6"},{"groupId":"OG001","value":"74.8","spread":"7.2"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Pulse Rate (Heart Rate).","description":"Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":"12.9"},{"groupId":"OG001","value":"88.0","spread":"13.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":"7.4"},{"groupId":"OG001","value":"74.4","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"5.8"},{"groupId":"OG001","value":"71.7","spread":"7.1"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Respiration Rate (Breathing Rate).","description":"Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"1.6"},{"groupId":"OG001","value":"17.5","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"1.4"},{"groupId":"OG001","value":"16.7","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"1.3"},{"groupId":"OG001","value":"16.4","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Clinically Relevant Laboratory Abnormalities","description":"Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":118},"commonTop":["Epigastric pain","Purulent bronchitis","Herpes simplex","Diarrhea","Dry mouth"]}}}